Figure 3

Cost-effectiveness scatter plot for patients with 20 > MMSE ≥ 10: donepezil versus memantine. Distribution of replications: 69.8% in lower right quadrant (donepezil dominant, leading to lower costs and higher QALYs), 25.2% in lower left quadrant (donepezil leads to lower costs and lower QALYs), 4.6% in upper left quadrant (donepezil dominated, leading to higher costs and lower QALYs), and 0.4% in the upper right quadrant (donepezil leads to higher costs and higher QALYs).